Paracelsian Announces Patent Approval & Kit Orders
ITHACA, N.Y., Oct. 5 /PRNewswire/ -- Paracelsian, Inc. (OTC Bulletin Board: PRLN - news) ITHACA, N.Y., announced today that the US Patent & Trademark Office has issued to Paracelsian Patent # 6,127,136 for the detection of dioxin-like compounds by the company's Ah-IMMUNOASSAY(TM) Kit.
Dioxins or dioxin-like compounds are environmental pollutants produced as unwanted byproducts of common industrial processes such as paper bleaching, incineration and chemical manufacturing. Dioxin-like compounds often occur as poorly defined mixtures of these compounds in a larger matrix of other materials that make their analysis and quantification difficult. There is considerable interest in the study, detection, monitoring and bioremediation of the compounds due to their environmental persistence, extreme chemical stability and extreme multiple toxicities to many organisms. There is also considerable worldwide demand for a user friendly and economical means of detecting dioxin in food and in environmental samples.
``This patent relates to new, improved and user-friendly methods of detecting dioxin-like compounds by detecting the transformed Ah receptor,'' said the inventor and Senior Scientist at Paracelsian, Dr. Geoffrey Wheelock.
``Paracelsian holds three other patents relative to its core technology the Ah-IMMUNOASSAY(TM), but this fourth patent is by far the most important,'' said Dr. T. Colin Campbell, President & CEO of Paracelsian. ``It gives us the protection that we need to continue to strengthen our presence in the worldwide dioxin detection marketplace,'' continued Dr. Campbell.
Paracelsian also announced today that Kubota Corporation (NYSE: KUB - news) is doubling their order for October 2000 for the 96-well Ah-IMMUNOASSAY(TM) Kits. Kubota last month appointed their first two distributors in Japan, Wako Pure Chemical and Veritas, and doubled their order of the 96-well kits within the first month of their sample distribution program.
In addition, Paracelsian on October 3, 2000 received its first kit order from Dynex Technologies, Inc in the Czech Republic. Paracelsian has also issued a Letter Of Intent to participate in a European wide dioxin-testing program for the food chain, to be administered by a French research center. ``This program will increase our exposure within the marketplace,'' concluded Dr. Campbell.
Paracelsian is a unique biotechnology company with three primary areas of focus. Paracelsian develops technologies useful in the detection and monitoring of environmental contaminants such as dioxin. Second, Paracelsian develops functional bioassays, which are the basis of its BioFIT(TM) Quality Assurance program for herbs, botanicals and other dietary supplements. And finally, Paracelsian's Internet business leverages extensive relationships in China, along with expertise in nutritional science, to provide an exchange of unique health products and research services.
Notice: This news release may contain forward-looking statements. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. |
